Immune Cell Modulation in Laryngotrachael Fibrosis
喉气管纤维化中的免疫细胞调节
基本信息
- 批准号:9750678
- 负责人:
- 金额:$ 23.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAdvanced DevelopmentAirAphoniaBiomechanicsBiomedical EngineeringBiometryBiopsyBlood VesselsBreathingCellsCicatrixClinicalClinical TrialsCommunication DisabilityDataDevelopmentDiseaseDysphoniaEngineeringEnvironmentEnzyme-Linked Immunosorbent AssayEthicsExperimental DesignsFRAP1 geneFacultyFibroblastsFibrosisFlow CytometryFunctional disorderFutureGene ExpressionGoalsHead and Neck SurgeryHistologicHistologyHumanImmuneImmune TargetingImmune responseImmunohistochemistryImmunologicsImmunologyIn SituIn VitroInfantInflammationInflammatoryInflammatory ResponseInjuryInstitutesInterdisciplinary StudyInterventionIntubationInvestigationK-Series Research Career ProgramsKnowledgeLarynxMechanicsMedicalMedical ResearchMentorsMentorshipMethodologyMethodsModelingMolecularMolecular BiologyMusOtolaryngologyOutcomePathologicPathologic ProcessesPatientsPharmaceutical PreparationsPhenotypePolymersProcessPropertyProteinsPublic Health SchoolsPulmonary FibrosisRegenerative MedicineResearchResearch PersonnelResearch TrainingResourcesRiskRoleRunningScienceSecondary toSignal TransductionSirolimusStenosisStentsSubglottis structureSurfaceSurgical ManagementT-LymphocyteTechniquesTestingTherapeuticTracheaTracheostomy procedureTubeVoiceWisconsinWound Healingairway obstructionbasebiocompatible polymerbody systemcareerclinical practicecytokinedesignendotrachealexperienceimprovedin vivoin vivo Modelinhibitor/antagonistmacrophagematerials sciencemedical schoolsmembermortalitymouse modelnovelpublic health relevanceresponseskillstherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Dr. Alexander Hillel is a junior faculty member in the Department of Otolaryngology-Head & Neck Surgery at the Johns Hopkins School of Medicine where his clinical practice is dedicated to the medical and surgical management of voice and airway disorders. With the support of a Mentored Career Development Award, Dr. Hillel seeks to better understand the inflammatory mechanisms of laryngotracheal fibrosis (LTF) and apply regenerative medicine techniques to its treatment. Specifically, Dr. Hillel will be focusing on mammalian target of rapamycin (mTOR), which has been shown to activate the same type of T cells and macrophages in pulmonary fibrosis that has been observed in early models of LTF. Ultimately, he plans to develop a drug-eluting stent to target the immune mechanisms. Aim 1 will characterize the inflammatory response to mechanical injury in the mouse trachea and then determine the role of mTOR in regulating macrophages and T-lymphocytes that precede LTF in a novel in vivo in situ mouse model. Aim 2 will characterize the role of macrophages, T-lymphocytes, and their inflammatory cytokines in patient with and patients at risk for developing LTF. Finally, Aim 2 will focus on identifying an ideal bioabsorbable polymer to engineer a drug-eluting airway stent targeting mechanisms identified in earlier aims. During the course of this proposal, Dr. Hillel will enhance his research knowledge and skills with coursework in immunology, biostatistics, and ethical research, receive directed mentorship by an interdisciplinary team of experienced researchers, and be immersed in the interdisciplinary research and clinical environments of the Johns Hopkins School of Medicine, Johns Hopkins Bloomberg School of Public Health, and the Laryngeal Research Group at The Wisconsin Institute of Medical Research in Madison, Wisconsin. This Career Development Award will provide Dr. Hillel with the resources that he needs to become an independent investigator and future leader in voice science research.
描述(由申请人提供):亚历山大希勒尔博士是约翰霍普金斯医学院耳鼻咽喉头颈外科系的初级教员,他的临床实践致力于嗓音和气道疾病的医疗和手术管理。在导师职业发展奖的支持下,Hillel博士寻求更好地了解喉气管纤维化(LTF)的炎症机制,并将再生医学技术应用于其治疗。具体而言,Hillel博士将专注于雷帕霉素(mTOR)的哺乳动物靶点,该靶点已被证明可以激活与LTF早期模型中观察到的肺纤维化中相同类型的T细胞和巨噬细胞。最终,他计划开发一种药物洗脱支架来靶向免疫机制。目的1将表征小鼠气管中机械损伤的炎症反应,然后在一种新的体内原位小鼠模型中确定mTOR在调节LTF之前的巨噬细胞和T淋巴细胞中的作用。目的2将描述巨噬细胞、T淋巴细胞及其炎性细胞因子在LTF患者和有发生LTF风险的患者中的作用。最后,目标2将重点确定一种理想的生物可吸收聚合物,以设计早期目标中确定的药物洗脱气道支架靶向机制。Hillel将通过免疫学,生物统计学和伦理研究课程提高他的研究知识和技能,接受经验丰富的研究人员跨学科团队的指导指导,并沉浸在约翰霍普金斯医学院,约翰霍普金斯彭博公共卫生学院,以及位于威斯康星州麦迪逊的威斯康星州医学研究所的喉部研究小组。这个职业发展奖将为Hillel博士提供他成为语音科学研究的独立研究者和未来领导者所需的资源。
项目成果
期刊论文数量(16)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Voice Outcomes in Laryngotracheal Stenosis: Impact of the Montgomery T-tube.
喉气管狭窄的声音结果:蒙哥马利 T 形管的影响。
- DOI:
- 发表时间:2018
- 期刊:
- 影响因子:0
- 作者:Dhillon,VaninderK;Akst,LeeM;Best,SimonR;Hillel,AlexanderT
- 通讯作者:Hillel,AlexanderT
Predictors of Posterior Glottic Stenosis: A Multi-Institutional Case-Control Study.
- DOI:10.1177/0003489415608867
- 发表时间:2016-03
- 期刊:
- 影响因子:0
- 作者:Hillel AT;Karatayli-Ozgursoy S;Samad I;Best SR;Pandian V;Giraldez L;Gross J;Wootten C;Gelbard A;Akst LM;Johns MM;North American Airway Collaborative (NoAAC)
- 通讯作者:North American Airway Collaborative (NoAAC)
Inaugural Symposium on Advanced Surgical Techniques in Adult Airway Reconstruction: Proceedings of the North American Airway Collaborative (NoAAC).
- DOI:10.1001/jamaoto.2016.4126
- 发表时间:2017-06-01
- 期刊:
- 影响因子:0
- 作者:Daniero JJ;Ekbom DC;Gelbard A;Akst LM;Hillel AT
- 通讯作者:Hillel AT
Factors Affecting Dilation Interval in Patients With Granulomatosis With Polyangiitis-Associated Subglottic and Glottic Stenosis.
- DOI:10.1177/01945998211004264
- 发表时间:2021-12
- 期刊:
- 影响因子:0
- 作者:Chen LW;Lina I;Motz K;Berges AJ;Ospino R;Seo P;Hillel AT
- 通讯作者:Hillel AT
Laryngotracheal Mucosal Surface Expression of Candidate Biomarkers in Idiopathic Subglottic Stenosis.
- DOI:10.1002/lary.28712
- 发表时间:2021-03
- 期刊:
- 影响因子:0
- 作者:Liu MM;Motz KM;Murphy MK;Yin LX;Ding D;Gelbard A;Hillel AT
- 通讯作者:Hillel AT
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Hillel其他文献
Alexander Hillel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Hillel', 18)}}的其他基金
Role of E-cadherin in epithelial barrier dysfunction and fibrosis in idiopathic subglottic stenosis
E-钙粘蛋白在特发性声门下狭窄上皮屏障功能障碍和纤维化中的作用
- 批准号:
10756248 - 财政年份:2023
- 资助金额:
$ 23.89万 - 项目类别:
Targeting mTOR regulation of T-lymphocytes and fibroblasts in Laryngotracheal Stenosis
喉气管狭窄中 T 淋巴细胞和成纤维细胞的靶向 mTOR 调节
- 批准号:
10594621 - 财政年份:2020
- 资助金额:
$ 23.89万 - 项目类别:
Targeting mTOR regulation of T-lymphocytes and fibroblasts in Laryngotracheal Stenosis
喉气管狭窄中 T 淋巴细胞和成纤维细胞的靶向 mTOR 调节
- 批准号:
10384685 - 财政年份:2020
- 资助金额:
$ 23.89万 - 项目类别:
Targeting mTOR regulation of T-lymphocytes and fibroblasts in Laryngotracheal Stenosis
喉气管狭窄中 T 淋巴细胞和成纤维细胞的靶向 mTOR 调节
- 批准号:
10635043 - 财政年份:2020
- 资助金额:
$ 23.89万 - 项目类别:
Targeting mTOR regulation of T-lymphocytes and fibroblasts in Laryngotracheal Stenosis
喉气管狭窄中 T 淋巴细胞和成纤维细胞的靶向 mTOR 调节
- 批准号:
10397577 - 财政年份:2020
- 资助金额:
$ 23.89万 - 项目类别:
Targeting mTOR regulation of T-lymphocytes and fibroblasts in Laryngotracheal Stenosis
喉气管狭窄中 T 淋巴细胞和成纤维细胞的靶向 mTOR 调节
- 批准号:
10613459 - 财政年份:2020
- 资助金额:
$ 23.89万 - 项目类别:
Metabolic Reprogramming in Laryngotracheal Stenosis
喉气管狭窄的代谢重编程
- 批准号:
9590279 - 财政年份:2018
- 资助金额:
$ 23.89万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 23.89万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 23.89万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 23.89万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 23.89万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 23.89万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 23.89万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 23.89万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 23.89万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 23.89万 - 项目类别: